Body Mass Index and the Risk of Atrial Fibrillation: A Mendelian Randomization Study

Mi Ma 1, Hong Zhi 2, Shengyi Yang 1, Evan Yi-Wen Yu 1,3 and Lina Wang 1,*

Abstract: Although observational studies have shown positive associations between body mass index (BMI) and the risk of atrial fibrillation (AF), the causal relationship is still uncertain owing to the susceptibility to confounding and reverse causation. This study aimed to examine the potential causality of BMI on AF by conducting a two-sample Mendelian randomization (TSMR) study. Methods: The independent genetic variants associated with BMI (n = 303) at the genome-wide significant level were derived as instrumental variables (IV) from the Genetic Investigation of Anthropometric Traits (GIANT) consortium consisting of 681,275 individuals of European ancestry. We then derived the outcome data from a GWAS meta-analysis comprised of 60,620 cases and 970,216 controls of European ancestry. The TSMR analyses were performed in five methods, namely inverse variance weighted (IVW) method, MR-Egger regression, the weighted median estimator (WME), the generalized summary data-based Mendelian randomization (GSMR), and the robust adjusted profile score (RAPS), to investigate whether BMI was causally associated with the risk of AF. Results: We found a genetically determined 1–standard deviation (SD) increment of BMI causally increased a 42.5% risk of AF (OR = 1.425; 95% CI, 1.346 to 1.509) based on the IVW method, which was consistent with the results of MR-Egger regression, WME, GSMR, as well as RAPS. The Mendelian randomization assumptions did not seem to be violated. Conclusion: This study provides evidence that higher BMI causally increased the risk of AF, suggesting control of BMI and obesity for prevention of AF.

Keywords: Mendelian randomization; BMI; atrial fibrillation; causal inference

1. Introduction

Atrial fibrillation (AF), the most common type of persistent clinical tachyarrhythmia, affected around 46.3 million individuals worldwide in 2016, according to The Global Burden of Disease project [1]. The current estimated prevalence of AF in adults is between 2% and 4% across the world [2], showing a 3-fold rise over the last 50 years based on data from the Framingham Heart Study [3]. It is biologically plausible that AF increases the risk of stroke and heart failure [4], resulting in the detrimental consequences of quality of life, disability, and even death. Moreover, given its high prevalence, AF is reported to be among the most expensive lifetime treatment of all diseases, which causes a considerable burden to the healthcare system [5].

As a surrogate marker of obesity, body mass index (BMI) has been a significant risk factor for obesity-related diseases, including AF. Several observational studies have reported a positive association between BMI and the risk of AF [6–9]. Nevertheless, it should be noted that the observed associations could not be well determined due to the
limitations of conventional statistical methods, namely potential confounders either or both reverse causalities [10].

Mendelian randomization (MR) is a method that can be of support to resolve these limitations [11–13]. In such cases, MR eliminates systematic biases by selecting genetic variants associated with exposure as instrumental variables (IVs), analogous to randomized controlled trials (RCT), alleles are allocated randomly at conception according to Mendel’s second law [12]. Through that, confounders are randomly distributed throughout the population. Followed by identifying the common variants in outcome data, the fundamental guideline utilized in MR can be used to contemplate the effect of a suspected environmental exposure (e.g., BMI) on disease risk. Given credit to the primarily increased genome-wide association studies (GWASs) in the past decade, other studies already used MR to establish causation between common cardiovascular diseases and blood pressure [14], tumor necrosis factor levels [15], and other risk factors [16,17]; however, the evidence for the effect of BMI on AF is still limited.

To overcome the limitations of conventional observational studies and shed light on whether BMI is a cause of AF, we used a two-sample Mendelian randomization (TSMR) approach and estimated associations between single nucleotide polymorphisms associated with BMI and risk of AF based on two independent publicly available GWASs [18,19].

2. Materials and Methods

2.1. Data Source

The exposure variable data for the genetic variants associated with BMI was derived from a GWAS meta-analysis in the Genetic Investigation of Anthropometric Traits (https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files, accessed on 28 April 2021) consortium (n = 681,275 individuals of European ancestry) [20]; similarly, the outcome variable data for AF was derived from a GWAS meta-analysis in six studies (The Nord-Trøndelag Health Study (HUNT), deCODE, the Michigan Genomics Initiative (MGI), DiscovEHR, UK Biobank, and the AFGen Consortium; http://csg.sph.umich.edu/willer/public/afib2018, accessed on 28 April 2021), which featured 60,620 AF cases and 970,216 controls of European ancestry [21].

2.2. Instrumental Variable Selection

The extracted genetic variants were selected as IVs to estimate causal effects of BMI on the risk of AF in accordance with the assumptions as follows: (1) being predictive of BMI, (2) being independent of confounders, and (3) no alteration of the outcome via an independent pathway other than BMI [22]. We firstly applied 751 SNPs associated with BMI at a genome-wide significance (p < 5 × 10^{-8}). After pruning for linkage disequilibrium (LD) (r^2 < 0.001; distance < 1000 kb), we obtained 507 independent SNPs. Each of the 507 BMI-associated SNPs was then examined the potential violations of the assumptions 2 and 3 based on the Phenoscanner database [23] (http://www.phenoscanner.medschl.cam.ac.uk/, accessed on 30 April 2021). Those SNPs, which significantly associated with any known risk factor (e.g., age, cardiovascular diseases, inflammation, dyslipidemia, and diabetes) for AF at a Bonferroni-correction p level (p < 9.9 × 10^{-5}; 0.05/507) were excluded from the further analysis. In addition, the SNPs with other pleiotropic pathways (e.g., physical inactivity, smoking, and drinking) were also removed [24–27]. The remaining SNPs were aggregated with the AF GWAS database, removing 6 SNPs that were not included in the AF database, and 10 palindromic SNPs with intermediate allele frequencies. In addition, we used the RacialMR R package [28] to perform Cochran’s Q test on the remaining SNPs and excluded 43 heterogeneous SNPs. We also examined possible pleiotropy of the selected SNPs by using the MR pleiotropy residual sum and outlier (MR-PRESSO) test [29] and the HEIDI (heterogeneity in dependent instrument) approach based on the GSMR analysis [30], in which 7 SNPs were excluded. In total, we applied 303 valid SNPs as IVs (Supplementary Figure S1).
2.3. Statistical Analysis

2.3.1. Mendelian Randomization Analyses

We employed the inverse variance weighted (IVW) method as the primary analysis to evaluate the causal effect between BMI and AF in our TSMR study. IVW calculates the exposure-outcome effect corresponding to each SNP using the Wald Ratio method, then performs a weighted linear regression with a forced intercept of zero. It achieved higher estimate accuracy and test power when IVs satisfied the three underlying assumptions [19]. To avoid the interference of unknown and unmeasurable confounders, we performed the MR-Egger regression (MR-Egger) [31], the weighted median estimator (WME) [32], the generalized summary data-based Mendelian randomization (GSMR) [30], and the robust adjusted profile score (RAPS) [33] to test the robustness of our results.

A reliable MR-Egger assessment of the causal effect is possible if the strength of the genetic instrument does not correlate with the impact of the instrument on the outcome, known as the InSIDE (Instrument Strength Independent of Direct Effect) assumption. Additionally, it should be noted that the MR-Egger estimate of causal effect will be biased towards a null result due to the NOME (No Measurement Error) assumption violation [34]. Therefore, we calculated the $I^2_{GX}$ statistics for assessing NOME violation and used simulation extrapolation (SIMEX) [35] to adjust this potential bias when the $I^2_{GX}$ value is lower than 0.9.

WME provided a consistent estimate of causality, even when up to 50% of genetic variants were invalid. GSMR analysis extends the SMR method using all the top associated SNPs at a genome-wide significance level for the exposure as IVs to test causality. Furthermore, unlike other methods, it accounts for both possible LD between SNPs and the sampling errors in the estimated effect sizes of the instruments on the exposures [30]. Considering that TSMR is challenged by measurement errors, pleiotropy, weak instruments, and selection bias, RAPS proposes an asymptotically averaged estimator by adjusting the contour score to improve robustness and efficiency [33].

2.3.2. Sensitivity Analyses

We calculated the $F$ statistics of the selected 303 SNPs to detect the strength of the IVs at a threshold of $F > 10$, which is typically recommended in MR analysis. The $F$ statistics was formulated as $F = \frac{R^2 (n - 1 - K)}{(1 - R^2) K}$, where $n$ represents the sample size, $K$ represents the number of IVs, and $R^2$ represents the proportion of variation explained by the SNPs in the exposure [18].

In addition, we assessed the heterogeneities between SNPs using Cochran’s Q-statistics derived from the IVW estimate and the $I^2$ statistic. The heterogeneity is more likely to be caused by sampling error when the $I^2$-value is closer to zero and is slight when the $I^2$-value is less than 0.25 [36].

We performed a leave-one-out analysis as a sensitivity analysis, accompanied with IVW to evaluate the combined effect value of the remaining SNPs. If the combined effect is consistent with the main effect analysis result, no single SNP has an excessive influence on the MR analysis.

All analyses were performed in R software (Version 4.0.5) using the R package (TwoSampleMR, gsmr and simex). Results were presented as the mean effect per 1-SD genetically determined increase in BMI together with the 95% confidence interval (CI); a two-sided $p$-value of less than 0.05 was considered statistically significant.

3. Results

3.1. Validity of Instrumental Variables

We included 303 SNPs explaining 2.5% ($R^2$) of the BMI variation as IVs for BMI-AF causal estimations. The $F$-statistics calculating from the first stage of the MR regression model was 61 [18,37]. The effect estimates of the associations between each SNP and both BMI and AF are reported in the Supplementary Table S1.
3.2. Mendelian Randomization

Table 1 shows the MR estimates of increased BMI with risk of AF. In particular, the results of five methods illustrated that the risk of AF increased with the increment of BMI, and all of them achieved consistently statistical significance. Based on the IVW method, we found a causal relationship between BMI and AF risk; a 1-standard deviation (SD) genetically determined increased BMI was causally associated with an additional 42.5% relative risk of AF ($N = 303$ SNPs; $OR = 1.425$; 95% CI = 1.346–1.509; $p = 3.720 \times 10^{-34}$). The estimates from MR-Egger regression, WME, GSMR, and RAPS analyses were consistent with these results (Table 1, Figures 1 and 2).

Table 1. MR estimates from each method of assessing the causal effect of BMI on the risk of AF.

| MR Method               | No. of SNPs | Beta   | SE    | $p$       | OR (95%CI)         |
|-------------------------|-------------|--------|-------|-----------|--------------------|
| Inverse variance weighted | 303         | 0.354  | 0.029 | $3.720 \times 10^{-34}$ | 1.425 (1.346–1.509) |
| MR-Egger                | 303         | 0.275  | 0.095 | $4.268 \times 10^{-3}$  | 1.316 (1.092–1.587) |
| Weighted median estimator | 303         | 0.336  | 0.045 | $7.330 \times 10^{-14}$ | 1.399 (1.281–1.527) |
| RAPS                    | 303         | 0.360  | 0.030 | <1 $\times 10^{-6}$   | 1.433 (1.350–1.521) |
| GSMR                    | 303         | 0.341  | 0.018 | $9.430 \times 10^{-77}$ | 1.406 (1.357–1.458) |
| MR-Egger SIMEX          | 303         | 0.361  | 0.028 | $6.180 \times 10^{-30}$ | 1.435 (1.357–1.517) |

Note: in the RAPS model, the estimated overdispersion parameter was minimal, so the simple model without overdispersion was used. Abbreviations: BMI, body mass index; AF, atrial fibrillation; MR, Mendelian randomization; SNP, single-nucleotide polymorphism; SE, standard error; OR, odds ratio; CI, confidence interval; RAPS, the robust adjusted profile score; GSMR, generalized summary data-based Mendelian randomization; SIMEX, simulation extrapolation.

Figure 1. Forest plot of six Mendelian Randomization estimators of the effect of body mass index on atrial fibrillation. Abbreviations: MR, Mendelian randomization; OR, odds ratio; CI, confidence interval; WMS, weighted median estimator; RAPS, the robust adjusted profile score; GSMR, generalized summary data-based Mendelian randomization; SIMEX, simulation extrapolation.
Figure 2. Scatter plot of SNPs associated with BMI and the risk of AF. The plot related the effect sizes of the SNP–BMI association (x-axis, SD units) and the SNP–AF associations (y-axis, log (OR)) with 95% confidence intervals. The regression slopes of the lines correspond to causal estimates using three Mendelian randomization methods (the inverse variance weighted method, MR-Egger regression, and weighted median estimator). Abbreviations: BMI, body mass index; AF, atrial fibrillation; MR, Mendelian randomization; SNP, single-nucleotide polymorphism.

Since the $I^2_{QX}$-statistic of the combined genetic variants for BMI was 0.778, the MR-Egger regression may violate the NOME assumption. Therefore, we performed a SIMEX of the MR-Egger estimate, which improved the estimated value of causal effect with a value of 1.435 closer to the result obtained by the IVW method (Table 1, Figure 1). The test for potential horizontal pleiotropy suggests no significant violation (regression intercepts of 0.0012, 95% CI = −0.0015–0.0040, p = 0.380; and −0.0002 95% CI = −0.0010–0.0006, p = 0.610), for with or without SIMEX correction, respectively. Neither Cochran’s Q test nor $I^2$-value supported the presence of heterogeneity for the analyses of BMI with AF (Q-statistic, 277.28; p = 0.84; $I^2 = 8.91\%$) (Table 2).

Table 2. The heterogeneity and pleiotropy tests of the instrumental variables.

| Cochran’s Q Test | $I^2$ | MR-Egger | MR-Egger SIMEX |
|------------------|-------|----------|----------------|
| Q                | p     | Intercept (95% CI) | $p$       | Intercept (95% CI) | $p$       |
| 277.28           | 0.84  | 0.0012 (−0.0015–0.0040) | 0.38       | −0.0002 (−0.0010–0.0006) | 0.61       |

Note: $I^2 = (Q − df)/Q$. Abbreviations: MR, Mendelian randomization; CI, confidence interval; SIMEX, simulation extrapolation.

In addition, there was no single SNP showing a significant impact on the MR estimation results based on leave-one-out analysis, with all significant estimates ranging from 1.42 to 1.43 (Supplementary Table S2). Figure 3 shows the distribution of the increased BMI effect on AF risks was symmetrical when a single SNP was used as an IV.
4. Discussion

In this TSMR study, we found a positive causality between the BMI and risk of AF, showing an average of 42.5% increased risk of AF with per 1-SD increment of in BMI. Our findings are in line with previous observational studies [38,39]. Given the random distribution of genotypes in the general population with respect to BMI, as well as the fixed nature of germline genotypes, these results should be less susceptible to confounding and reverse causation than those generated by observational studies.

Although the pathophysiological mechanisms sustaining the effect of BMI on AF have yet to be elucidated entirely, as the surrogate marker of obesity, the findings in previous studies suggest obesity may contribute to this unfortunate outcome through multi-pathways, such as hemodynamic changes, altering epicardial adipose tissue, atrial remodeling, and inflammation [40,41].

Excessive adipose accumulation increases total and central blood volume to help perfuse excess tissue, which results in a high cardiac output state and left ventricular (LV) enlargement. In most obese individuals, augmentation of cardiac output predisposes to heart structure remodeling, which lays up the basis for AF [42,43]. In addition, neurohumoral and metabolic disorders caused by obesity, including increased insulin resistance, activation of the renin–angiotensin–aldosterone system, and autonomic dysfunction, also drive cardiac changes in the structure and function [44]. In recent years, the role of epicardial adipose tissue, providing paracrine and autocrine functions in the development of AF, has been recognized [45,46]. The adipokines secreted by epicardial fat may have a significant pro-fibrotic effect on the atrial myocardium and could facilitate atrial myocardial remodeling [46,47]. Other probable mechanisms, such as fat infiltration, inflammation, and oxidative stress, caused by epicardial fat are also implicated in the initiation and maintenance of arrhythmogenesis [45]. Although the mechanism has not been confirmed, studies have shown that the amount of pericardial fat is associated with an increased prevalence of AF [48]. In addition, the systemic pro-inflammatory state characterized by obesity is an essential contributor as inflammation is strongly related to AF [49].

This TSMR analysis had several strengths; (1) Compared with traditional observational studies, the MR method enabled us to provide more reliable effect estimates as it reduced the impact of confounders and reverse causality; (2) the included summary data were based on individuals of European descent, which largely mitigated the effects of population stratification; (3) the identification and selection of the IVs were through a rigorous procedure, which reduced the bias due to the unsuitable IVs.
Our study also had certain limitations: (1) we were unable to perform a stratified analysis upon gender and age due to the lack of individual information in secondary data; (2) the MR method assumes a linear association of exposure-outcome effect; hence the nonlinear relationship between BMI and AF risk was unable to be assessed; (3) the European ancestry of the samples hampered the promotion of our findings to other populations.

5. Conclusions

In summary, this TSMR study supports the genetic causality between the increased BMI and AF risks. This finding adds to further evidence that maintaining a healthy BMI is critical for individuals at risk of AF.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu14091878/s1, Figure S1: Flow chart for quality control of the instrumental variables for MR analysis; Table S1: Characteristics of the SNPs associated with BMI and with AF; Table S2: The combined effect estimators of the remaining 302 SNPs obtained by IVW after removing each SNP.

Author Contributions: Formal analysis, M.M.; methodology, M.M. and S.Y.; software, M.M., S.Y. and H.Z.; supervision, L.W.; validation, L.W.; visualization, M.M. and S.Y.; writing—original draft, M.M.; writing—review and editing, L.W. and E.Y.-W.Y.; project administration, L.W. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the National Natural Science Foundation of China (81673259), Natural Science Foundation of Jiangsu Province, China (BK20161435) and Jiangsu Commission of Health (H2019079).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: These data were derived from the following resources available in the public websites: the exposure data for BMI https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files, and the outcome data for AF http://csg.sph.umich.edu/willier/public/afib2018 (all accessed on 28 April 2021).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Benjamin, E.J.; Muntner, P.; Alonso, A.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Das, S.R.; et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019, 139, e56-e528. [CrossRef] [PubMed]

2. Hindricks, G.; Potpara, T.; Dagres, N.; Arbello, E.; Bax, J.J.; Blomstrom-Lundqvist, C.; Boriani, G.; Castella, M.; Dan, G.A.; Dilaveris, P.E.; et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021, 42, 373–498. [CrossRef] [PubMed]

3. Schnabel, R.B.; Yin, X.; Gona, P.; Larson, M.G.; Beiser, A.S.; McManus, D.D.; Newton-Cheh, C.; Lubitz, S.A.; Magnani, J.W.; Ellinor, P.T.; et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study. Lancet 2015, 386, 154–162. [CrossRef]

4. Krijthe, B.P.; Kunst, A.; Benjamin, E.J.; Lip, G.Y.; Franco, O.H.; Hofman, A.; Witteman, J.C.; Stricker, B.H.; Heeringa, J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 2013, 34, 2746–2751. [CrossRef]

5. Ball, J.; Carrington, M.J.; McMurray, J.J.; Stewart, S. Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century. Int. J. Cardiol. 2013, 167, 1807–1824. [CrossRef]

6. Kim, Y.G.; Han, K.D.; Choi, J.I.; Boo, K.Y.; Kim, D.Y.; Oh, S.K.; Lee, K.N.; Shim, J.; Kim, J.S.; Kim, Y.H. The impact of body weight and diabetes on new-onset atrial fibrillation: A nationwide population based study. Cardiovasc. Diabetol. 2019, 18, 128. [CrossRef]

7. Asad, Z.; Abbas, M.; Javed, I.; Korantzopoulos, P.; Stavrakis, S. Obesity is associated with incident atrial fibrillation independent of gender: A meta-analysis. J. Cardiovasc. Electrophysiol. 2018, 29, 725–732. [CrossRef]

8. Lee, H.; Choi, E.K.; Lee, S.H.; Han, K.D.; Rhee, T.M.; Park, C.S.; Lee, S.R.; Choe, W.S.; Lim, W.H.; Kang, S.H.; et al. Atrial fibrillation risk in metabolically healthy obesity: A nationwide population-based study. Int. J. Cardiol. 2017, 240, 221–227. [CrossRef]
9. Nystrom, P.K.; Carlsson, A.C.; Leander, K.; de Faire, U.; Hellenius, M.L.; Gigante, B. Obesity, metabolic syndrome and risk of atrial fibrillation: A Swedish, prospective cohort study. PLoS ONE 2015, 10, e0127111. [CrossRef]

10. Carreras-Torres, R.; Johansson, M.; Haycock, P.C.; Relton, C.L.; Davey Smith, G.; Brennan, P.; Martin, R.M. Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank. BMJ 2018, 361, k1767. [CrossRef]

11. Katan, M.B. Commentary: Mendelian Randomization, 18 years on. Int. J. Epidemiol. 2004, 33, 10–11. [CrossRef]

12. Smith, G.D.; Ebrahim, S. ‘Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 2003, 32, 1–22. [CrossRef]

13. Davey Smith, G.; Hemani, G. Mendelian randomization: Genetic anchors for causal inference in epidemiological studies. Hum. Mol. Genet. 2014, 23, R89–R98. [CrossRef]

14. Georgiopoulos, G.; Ntritsos, G.; Stamatelopoulos, K.; Tsiofis, C.; Aimo, A.; Masi, S.; Evangelou, E. The relationship between blood pressure and risk of atrial fibrillation: A Mendelian randomization study. Eur. J. Prev. Cardioil. 2021, 28, 1617. [CrossRef]

15. Yuan, S.; Carter, P.; Bruzelius, M.; Vithayathil, M.; Kar, S.; Mason, A.M.; Lin, A.; Burgess, S.; Larsson, S.C. Effects of tumour necrosis factor on cardiovascular disease and cancer: A two-sample Mendelian randomization study. EBioMedicine 2020, 59, 102956. [CrossRef]

16. Wang, T.; Xu, L. Circulating Vitamin E Levels and Risk of Coronary Artery Disease and Myocardial Infarction: A Mendelian Randomization Study. Nutrients 2019, 11, 2153. [CrossRef]

17. Allara, E.; Morani, G.; Carter, P.; Gkatzionis, A.; Zuber, V.; Foley, C.N.; Rees, J.M.B.; Mason, A.M.; Bell, S.; Gill, D.; et al. Genetic Determinants of Lipids and Cardiovascular Disease Outcomes: A Wide-Angled Mendelian Randomization Investigation. Circ. Genom. Precis. Med. 2019, 12, e002711. [CrossRef]

18. Pierce, B.L.; Burgess, S. Efficient design for Mendelian randomization studies: Subsample and 2-sample instrumental variable estimators. Am. J. Epidemiol. 2013, 178, 1177–1184. [CrossRef]

19. Burgess, S.; Butterworth, A.; Thompson, S.G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol. 2013, 37, 658–665. [CrossRef]

20. Yengo, L.; Sidorenko, J.; Kemper, K.E.; Zheng, Z.; Wood, A.R.; Weedon, M.N.; Frayling, T.M.; Hirshhorn, J.; Yang, J.; Visscher, P.M.; et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 70000 individuals of European ancestry. Hum. Mol. Genet. 2018, 27, 3641–3649. [CrossRef]

21. Nielsen, J.B.; Thorolfsdottir, R.B.; Fritsche, L.G.; Zhou, W.; Skov, M.W.; Graham, S.E.; Herron, T.J.; McCarthy, S.; Schmidt, E.M.; Sveinbjornsson, G.; et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat. Genet. 2018, 50, 1234–1239. [CrossRef]

22. Larsson, S.C. Mendelian randomization as a tool for causal inference in human nutrition and metabolism. Curr. Opin. Lipidol. 2021, 32, 1–8. [CrossRef]

23. Staley, J.R.; Blackshaw, J.; Kamat, M.A.; Ellis, S.; Surendran, P.; Sun, B.B.; Paul, D.S.; Freitag, D.; Burgess, S.; Danesh, J.; et al. PhenoScanner: A database of human genotype-phenotype associations. Bioinformatics 2016, 32, 3207–3209. [CrossRef]

24. Da Silva, R.M. Influence of Inflammation and Atherosclerosis in Atrial Fibrillation. Curr. Atheroscler. Rep. 2017, 19, 2. [CrossRef]

25. Kallistratos, M.S.; Poulimenos, L.E.; Manolis, A.J. Atrial fibrillation and arterial hypertension. Pharmacol. Res. 2018, 128, 322–326. [CrossRef]

26. Chung, M.K.; Eckhardt, L.L.; Chen, L.Y.; Ahmed, H.M.; Gopinathannair, R.; Joglar, J.A.; Noseworthy, P.A.; Pack, Q.R.; Sanders, P.; Trulock, K.M.; et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement from the American Heart Association. Circulation 2020, 141, e750–e772. [CrossRef]

27. Yao, Y.S.; Liu, F.; Wang, Y.Y.; Liu, Z.Z. Lipid levels and risk of new-onset atrial fibrillation: A systematic review and dose-response meta-analysis. Clin. Cardiol. 2020, 43, 933–943. [CrossRef]

28. Bowden, J.; Spiller, W.; Del Greco, M.F.; Sheehan, N.; Thompson, J.; Minelli, C.; Davey Smith, G. Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression. Int. J. Epidemiol. 2018, 47, 2100. [CrossRef][PubMed]

29. Verbanck, M.; Chen, C.Y.; Neale, B.; Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 2018, 50, 693–698. [CrossRef][PubMed]

30. Zhu, Z.; Zheng, Z.; Zhang, F.; Wu, Y.; Trzaskowski, M.; Maier, R.; Robinson, M.R.; McGrath, J.J.; Visscher, P.M.; Wray, N.R.; et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat. Commun. 2018, 9, 224. [CrossRef][PubMed]

31. Bowden, J.; Davey Smith, G.; Burgess, S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 2015, 44, 512–525. [CrossRef]

32. Bowden, J.; Davey Smith, G.; Haycock, P.C.; Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet. Epidemiol. 2016, 40, 304–314. [CrossRef]

33. Zhao, Q.Y.; Wang, J.S.; Hemani, G.; Bowden, J.; Small, D.S. Statistical Inference in Two-Sample Summary-Data Mendelian Randomization Using Robust Adjusted Profile Score. Ann. Stat. 2020, 48, 1742–1769. [CrossRef]

34. Bowden, J.; Del Greco, M.F.; Minelli, C.; Davey Smith, G.; Sheehan, N.A.; Thompson, J.R. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: The role of the I2 statistic. Int. J. Epidemiol. 2016, 45, 1961–1974. [CrossRef]
35. Kuchenhoff, H.; Mwalili, S.M.; Lesaffre, E. A general method for dealing with misclassification in regression: The misclassification SIMEX. *Biometrics* 2006, 62, 85–96. [CrossRef]
36. Hatala, R.; Keitz, S.; Wyer, P.; Guyatt, G.; Evidence-Based Medicine Teaching Tips Working, G. Tips for learners of evidence-based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. *CMAJ* 2005, 172, 661–665. [CrossRef]
37. Stock, J.H.; Wright, J.H.; Yogo, M. A survey of weak instruments and weak identification in generalized method of moments. *J. Bus. Econ. Stat.* 2002, 20, 518–529. [CrossRef]
38. Andersen, K.; Rasmussen, F.; Neovius, M.; Tynelius, P.; Sundstrom, J. Body size and risk of atrial fibrillation: A cohort study of 1.1 million young men. *J. Intern. Med.* 2018, 283, 346–355. [CrossRef]
39. Feng, T.; Vegard, M.; Strand, L.B.; Laugsand, L.E.; Morkedal, B.; Aune, D.; Vatten, L.; Ellekjaer, H.; Løennechen, J.P.; Mukamal, K.; et al. Weight and weight change and risk of atrial fibrillation: The HUNT study. *Eur. Heart J.* 2019, 40, 2859–2866. [CrossRef]
40. Javed, S.; Gupta, D.; Lip, G.Y.H. Obesity and atrial fibrillation: Making inroads through fat. *Eur. Heart J. Cardiovasc. Pharm.* 2021, 7, 59–67. [CrossRef]
41. Lavie, C.J.; Pandey, A.; Lau, D.H.; Alpert, M.A.; Sanders, P. Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and Prognosis: Effects of Weight Loss and Exercise. *J. Am. Coll. Cardiol.* 2017, 70, 2022–2035. [CrossRef]
42. Stritzke, J.; Markus, M.R.; Duderstadt, S.; Lieb, W.; Luchner, A.; Doring, A.; Keil, U.; Herse, H.W.; Schunkert, H.; Investigators, M.K. The aging process of the heart: Obesity is the main risk factor for left atrial enlargement during aging the MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. *J. Am. Coll. Cardiol.* 2009, 54, 1982–1989. [CrossRef]
43. Munger, T.M.; Dong, Y.X.; Masaki, M.; Oh, J.K.; Mankad, S.V.; Borlaug, B.A.; Asirvatham, S.J.; Shen, W.K.; Lee, H.C.; Bielinski, S.J.; et al. Electrophysiological and hemodynamic characteristics associated with obesity in patients with atrial fibrillation. *J. Am. Coll. Cardiol.* 2012, 60, 851–860. [CrossRef]
44. Alpert, M.A.; Omran, J.; Bostick, B.P. Effects of Obesity on Cardiovascular Hemodynamics, Cardiac Morphology, and Ventricular Function. *Curr. Obes. Rep.* 2016, 5, 424–434. [CrossRef]
45. Wong, C.X.; Ganesan, A.N.; Selvanayagam, J.B. Epicardial fat and atrial fibrillation: Current evidence, potential mechanisms, clinical implications, and future directions. *Eur. Heart J.* 2017, 38, 1294–1302. [CrossRef]
46. Hatem, S.N.; Sanders, P. Epicardial adipose tissue and atrial fibrillation. *Cardiovasc. Res.* 2014, 102, 205–213. [CrossRef]
47. Ventecelet, N.; Guglielmi, V.; Balse, E.; Gaborit, B.; Cotillard, A.; Atassi, F.; Amour, J.; Leprince, P.; Dutour, A.; Clement, K.; et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. *Eur. Heart J.* 2015, 36, 795–805. [CrossRef]
48. Thanassoulis, G.; Massaro, J.M.; O’Donnell, C.J.; Hoffmann, U.; Levy, D.; Ellinor, P.T.; Wang, T.J.; Schnabel, R.B.; Vasan, R.S.; Fox, C.S.; et al. Pericardial fat is associated with prevalent atrial fibrillation: The Framingham Heart Study. *Circ. Arrhythm. Electrophysiol.* 2010, 3, 345–350. [CrossRef]
49. Harada, M.; Van Wagoner, D.R.; Nattel, S. Role of inflammation in atrial fibrillation pathophysiology and management. *Circ. J.* 2015, 79, 495–502. [CrossRef]